Phase 1 study of BBT-015 in healthy human subjects.
Phase of Trial: Phase I
Latest Information Update: 04 May 2018
At a glance
- Drugs BBT-015 (Primary) ; Pegfilgrastim
- Indications Acute radiation syndrome; Neutropenia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 04 May 2018 Status changed from recruiting to completed, according to a Bolder BioTechnology media release.
- 27 Apr 2018 Results presented in a Bolder BioTechnology Media Release.
- 08 Aug 2017 New trial record